Trailing-twelve-month (TTM) revenue is $14.35 Billion with a year-over-year growth of +6.41%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $3,563,500,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-31 |
| Q4 FY2025Period ended 2025-12-31 | $3,515,800,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-24 |
| Q1 FY2026Period ended 2026-03-31 | $3,537,600,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-04 |
| Q2 FY2026Period ended 2026-06-30 | $3,731,100,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $14,348,000,000 |
Current P/S: $25,546,280,000 market capitalization ÷ $14,348,000,000 TTM revenue = 1.78x.
Market capitalization source: FMP quote. Quote observed 2026-09-11T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $3.73B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-12T00:15:46.919Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-10.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2021-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Covance Drug Development | $2.3B | $5.8B | $5.7B | $2.8B | N/A | N/A |
| LabCorp Diagnostics | $6.7B | $10.4B | $9.2B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20162016-12-31 · USD | FY20172017-12-31 · USD | FY20182018-12-31 · USD | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD |
|---|---|---|---|---|---|---|
| CANADA | $296M | $328M | N/A | N/A | N/A | N/A |
| Europe | N/A | N/A | N/A |
$14.35B
$14.35 Billion
+6.41%
vs. $13.48B a year ago (TTM)
(2.62%)
5 Year compound annual growth rate
1 Year
+6.41%
3 Year
+4.39%
5 Year
(2.62%)
10 Year
+4.30%
15 Year
+6.81%
20 Year
+7.37%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $13.95B | +$942.80M | +7.25% |
| 2024 | $13.01B | +$847.30M | +6.97% |
| 2023 | $12.16B | +$297.70M | +2.51% |
| 2022 | $11.86B | ($1.27B) | (9.68%) |
| 2021 | $13.14B | ($842.40M) | (6.03%) |
| 2020 |
TTM Growth
+6.41%
3-Year CAGR
+4.39%
5-Year CAGR
(2.62%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-12T00:15:46.919Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-10.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $9.4B |
| $10.1B |
| $10.9B |
| N/A |
| $1.5B |
| $2.1B |
| North America | N/A | N/A | N/A | N/A | $11.5B | $13.1B |
|---|
| Other countries | N/A | $858M | $1.2B | $1.2B | $941M | $976M |
|---|
| SWITZERLAND | $451M | $484M | N/A | N/A | N/A | N/A |
|---|
| UNITED KINGDOM | N/A | $302M | N/A | N/A | N/A | N/A |
|---|
| UNITED STATES | N/A | $8.2B | N/A | N/A | N/A | N/A |
|---|
| $13.98B |
| +$2.42B |
| +20.98% |
| 2019 | $11.55B | +$221.40M | +1.95% |
| 2018 | $11.33B | +$892.00M | +8.54% |
| 2017 | $10.44B | +$799.60M | +8.29% |
| 2016 | $9.64B | +$961.70M | +11.08% |
